Marilyn S Huckans1, Aaron D Blackwell, Todd A Harms, Peter Hauser. 1. Northwest Hepatitis C Resource Center, Portland Veterans Affairs Medical Center, and Department of Psychiatry at Oregon Health and Science University 97239, USA. marilyn.huckans@med.va.gov
Abstract
OBJECTIVE: Rates of hepatitis C (HCV) infection, testing, and treatment were compared among patients with schizophrenia, a substance use disorder, or co-occurring schizophrenia or schizoaffective disorder and a substance use disorder and a control group. METHODS: Information about 293,445 patients of the Northwest Veterans Healthcare Administration was obtained. RESULTS: The substance use disorder group constituted 13.6 percent of the sample; the schizophrenia group, 1.6 percent; and the co-occurring-disorders group, 1.4 percent. Respectively, these groups were approximately four, two, and six times as likely as the control group to receive HCV testing and about seven, two, and eight times as likely to be infected. The rate of interferon (IFN) therapy was significantly lower for the substance use group and the group with co-occurring disorders. However, the magnitude of the differences was not substantial, suggesting that these high-risk groups were not excluded from IFN therapy.
OBJECTIVE: Rates of hepatitis C (HCV) infection, testing, and treatment were compared among patients with schizophrenia, a substance use disorder, or co-occurring schizophrenia or schizoaffective disorder and a substance use disorder and a control group. METHODS: Information about 293,445 patients of the Northwest Veterans Healthcare Administration was obtained. RESULTS: The substance use disorder group constituted 13.6 percent of the sample; the schizophrenia group, 1.6 percent; and the co-occurring-disorders group, 1.4 percent. Respectively, these groups were approximately four, two, and six times as likely as the control group to receive HCV testing and about seven, two, and eight times as likely to be infected. The rate of interferon (IFN) therapy was significantly lower for the substance use group and the group with co-occurring disorders. However, the magnitude of the differences was not substantial, suggesting that these high-risk groups were not excluded from IFN therapy.
Authors: Seth Himelhoch; John F McCarthy; Dara Ganoczy; Deborah Medoff; Amy Kilbourne; Richard Goldberg; Lisa Dixon; Frederic C Blow Journal: Psychosomatics Date: 2009 Jan-Feb Impact factor: 2.386
Authors: Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark Journal: Subst Abuse Date: 2008-04-28
Authors: Ellen M Janssen; Emma E McGinty; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit Journal: Gen Hosp Psychiatry Date: 2015-03-14 Impact factor: 3.238
Authors: Peter Hauser; Benjamin J Morasco; Alex Linke; Dannell Bjornson; Samantha Ruimy; Annette Matthews; Aly Rifai; David W Indest; Jennifer M Loftis Journal: Psychosomatics Date: 2009 Sep-Oct Impact factor: 2.386
Authors: Marilyn Huckans; Adriana Seelye; Tiffany Parcel; Lisa Mull; Jonathan Woodhouse; Danell Bjornson; Bret E Fuller; Jennifer M Loftis; Benjamin J Morasco; Anna W Sasaki; Daniel Storzbach; Peter Hauser Journal: J Int Neuropsychol Soc Date: 2009-01 Impact factor: 2.892
Authors: Marilyn Huckans; Alex Mitchell; Shital Pavawalla; Benjamin J Morasco; Samantha Ruimy; Jennifer M Loftis; Muhamad A Rifai; Peter Hauser Journal: Antivir Ther Date: 2010